Lifeworks Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Lifeworks Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.35M	Buy	3,022 +99	+3%	+$46.2K	0.17%	111
2025 Q4	$1.33M	Buy	2,923 +9	+0.3%	+$3.88K	0.17%	121
2025 Q3	$1.14M	Buy	2,914 +260	+10%	+$109K	0.15%	126
2025 Q2	$1.18M	Sell	2,654 -501	-16%	-$231K	0.18%	113
2025 Q1	$1.53M	Sell	3,155 -529	-14%	-$247K	0.25%	93
2024 Q4	$1.48M	Sell	3,684 -8,169	-69%	-$3.79M	0.27%	98
2024 Q3	$5.51M	Sell	11,853 -560	-5%	-$269K	1.08%	26
2024 Q2	$5.82M	Buy	12,413 +1,816	+17%	+$788K	1.62%	16
2024 Q1	$4.43M	Buy	10,597 +1,496	+16%	+$632K	1.24%	25
2023 Q4	$3.7M	Buy	9,101 +738	+9%	+$273K	1.28%	23
2023 Q3	$2.91M	Buy	+8,363	New	+$2.92M	1.13%	26

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Lifeworks Advisors's VRTX Position: Q1 2026 in Review

Lifeworks Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 3.4% in Q1 2026, buying an estimated $46.2K and bringing the position to 3,022 shares worth $1.35M. The position accounts for 0.17% of the portfolio, ranked #111.

Lifeworks Advisors first reported a position in VRTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $5.82M in Q2 2024. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Lifeworks Advisors held 3,022 shares of Vertex Pharmaceuticals worth $1.35M as of Q1 2026.
Lifeworks Advisors bought 99 Vertex Pharmaceuticals shares in Q1 2026, an estimated $46.2K.
Vertex Pharmaceuticals made up 0.17% of Lifeworks Advisors's portfolio in Q1 2026, its #111 holding.
Lifeworks Advisors first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Lifeworks Advisors's Vertex Pharmaceuticals position peaked at $5.82M in Q2 2024.
1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Lifeworks Advisors's 13F filing for Q1 2026, filed 4 May 2026.